



Australian Government
Department of Health and Ageing



Australia and New Zealand Horizon Scanning Network

ANZHSN

AN INITIATIVE OF THE NATIONAL, STATE AND
TERRITORY GOVERNMENTS OF AUSTRALIA
AND THE GOVERNMENT OF NEW ZEALAND

Horizon Scanning Technology

Prioritising Summary

**Narrow band imaging for the improved
detection of pre-cancerous lesions
during colonoscopy**

November 2008



© Commonwealth of Australia 2008

ISBN

Publications Approval Number:

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the *Copyright Act 1968*, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Canberra ACT 2600 or posted at <http://www.ag.gov.au/cca>

Electronic copies can be obtained from <http://www.horizonscanning.gov.au>

Enquiries about the content of the report should be directed to:

HealthPACT Secretariat
Department of Health and Ageing
MDP 106
GPO Box 9848
Canberra ACT 2606
AUSTRALIA

DISCLAIMER: This report is based on information available at the time of research cannot be expected to cover any developments arising from subsequent improvements health technologies. This report is based on a limited literature search and is not a definitive statement on the safety, effectiveness or cost-effectiveness of the health technology covered.

The Commonwealth does not guarantee the accuracy, currency or completeness of the information in this report. This report is not intended to be used as medical advice and intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used therapeutic purposes or as a substitute for a health professional's advice. The Commonwealth does not accept any liability for any injury, loss or damage incurred by use of or reliance the information.

The production of this Horizon scanning prioritising summary was overseen by the Health Policy Advisory Committee on Technology (HealthPACT), a sub-committee of the Medical Services Advisory Committee (MSAC). HealthPACT comprises representatives from departments in all states and territories, the Australia and New Zealand governments; and ASERNIP-S. The Australian Health Ministers' Advisory Council (AHMAC) supports HealthPACT through funding.

This Horizon scanning prioritising summary was prepared by Adrian Purins and Professor Janet Hiller from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Discipline of Public Health, School of Population Health and Clinical Practice, Mail Drop DX 650 545, University of Adelaide, Adelaide, SA, 5005.

PRIORITISING SUMMARY

REGISTER ID: 000414

NAME OF TECHNOLOGY: NARROW BAND IMAGING

PURPOSE AND TARGET GROUP: IMAGING MODALITY FOR THE IMPROVED DETECTION OF PRECANCEROUS LESIONS DURING COLONOSCOPY

STAGE OF DEVELOPMENT (IN AUSTRALIA):

- | | |
|---|--|
| <input type="checkbox"/> Yet to emerge | <input type="checkbox"/> Established |
| <input type="checkbox"/> Experimental | <input checked="" type="checkbox"/> Established <i>but</i> changed indication or modification of technique |
| <input type="checkbox"/> Investigational | <input type="checkbox"/> Should be taken out of use |
| <input type="checkbox"/> Nearly established | |

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION APPROVAL

- | | |
|--|-------------|
| <input type="checkbox"/> Yes | ARTG number |
| <input type="checkbox"/> No | |
| <input checked="" type="checkbox"/> Not applicable | |

INTERNATIONAL UTILISATION:

COUNTRY	LEVEL OF USE		
	Trials Underway or Completed	Limited Use	Widely Diffused
Germany	✓		
United States	✓		
Japan	✓		

IMPACT SUMMARY:

Companies that produce standard imaging equipment such as Olympus provide high resolution endoscopes capable of performing narrow band imaging. Although narrow band imaging is a relatively new imaging modality, it has been in use in Australia, mainly for patients with Barrett's oesophagus. This prioritising summary examines the use of narrow band imaging for the new indication of the detection of precancerous gastric and colorectal lesions. The technology would be made available through specialist hospitals for patients undergoing a conventional bronchoscopy or endoscopy.

BACKGROUND

Narrow band imaging (NBI) is an imaging technique that exploits the specific transmissibility and absorption characteristics of specific wavelengths of light. Longer

wavelengths of light penetrate further into tissue and different wavelengths are absorbed differently by structures within the tissue. Specifically, blue light (415nm) allows the visualisation of the superficial capillary network as it does not penetrate the tissue to a great extent. Green light (540nm) penetrates further into the tissue allowing the visualisation of deeper structures such as sub-epithelial vessels. When images from the two light sources are combined a high contrast image of the tissue surface is generated.




Figure 1 NBI image acquisition. Blue light only penetrates the near surface, whereas green light penetrates to deeper structures (left). The combined image shows the capillaries in brown and the underlying veins in blue (right).

Lesions visualised with NBI can be categorised using two different techniques. One method involves the analysis of microvasculature, with neoplastic lesions displaying increased or abnormal microvessel density. A second method developed by Kudo et al (1994) involves analysis of the “pit pattern” of a lesion which results from the surface structures and superficial mucosal capillaries. The Kudo pit pattern allows the lesion to be graded on a scale from nonadenomatous to adenomatous¹. These methods are applicable to a variety of tissue types, including the colon.

CLINICAL NEED AND BURDEN OF DISEASE

In 2004 there were 12,977 new cases of colorectal cancer diagnosed within Australia. According to the AIHW there are no national prevalence data available for colorectal cancer (AIHW 2007). In 2006-07 there were a total of 230,911 separations for colonoscopy as recorded under 4 categories (G43Z Complex Colonoscopy, G44A Other Colonoscopy W Catastrophic or Severe CC, G44B Other Colonoscopy W/O Catastrophic or Severe CC, G44C Other Colonoscopy Sameday) (AIHW 2008). It is not clear how many of these separations are related to colorectal cancer diagnosis.

¹ Adenomatous lesions are not necessarily cancerous but have the risk of progression to malignancy.

DIFFUSION

While NBI is currently in use in Australia for Barrett's oesophagus, no evidence was found indicating NBI is used during colonoscopy for colorectal cancer diagnosis. However, a recent demonstration (August 2008) of the technique was conducted at the Royal Brisbane and Women's Hospital, by Dr Omori, a gastrointestinal surgeon from Kawasaki Hospital, Japan.

COMPARATORS

Colonoscopy is the gold standard for diagnosis of potentially cancerous polyps. Being the gold standard, it is difficult to assess the accuracy of colonoscopy. As newer techniques emerge it is evident that colonoscopy is lacking in some areas such as amount of surface area of the colon able to be visualised (East et al. 2007), the difficulty of detecting flat lesions with conventional colonoscopy (Dekker and Fockens 2005), and the estimated polyp miss rate of 10-20 per cent (Bensen et al. 1999; Robertson et al. 2005).

SAFETY AND EFFECTIVENESS ISSUES

Several studies have investigated the diagnostic ability of NBI for colorectal lesions compared to conventional white light colonoscopy and histology. Adler investigated NBI in a trial where patients presenting for routine colonoscopy diagnosis were randomly assigned to either conventional or NBI colonoscopy. The study involved 401 eligible patients (200 NBI, 201 conventional colonoscopy) and found that the detection rate of adenomas was higher in the NBI group (23%) than the conventional group (17%), although this did not reach significance ($p= 0.129$). There was an apparent training effect involving the conventional method, where the first 100 patients showed a 26.5 per cent adenoma detection rate for NBI and eight per cent for conventional colonoscopy, however the last 100 patients had an adenoma detection rate of 25.5 and 26.5 per cent for NBI and conventional colonoscopy, respectively. The authors speculated that the improved polyp detection using NBI may increase the ability of the clinicians to recognise polyps using conventional colonoscopy (Adler et al 2008) (Level III-2 diagnostic evidence).

A second study randomised 276 patients presenting for routine colonoscopy to NBI or conventional colonoscopy. After either NBI or conventional colonoscopy was carried out a subsequent examination with conventional colonoscopy was performed as the reference standard. The neoplasm miss rate was calculated against the reference standard and was similar for both techniques (NBI = 17/135 (12.6%) vs conventional colonoscopy = 17/141 (12.1%). The miss rate for *advanced adenomas* was less than one per cent (Kaltenbach et al 2008) (Level III-2 diagnostic evidence).

Inoue et al investigated NBI versus conventional colonoscopy in a prospectively recruited population of 243 patients who were randomly assigned to either NBI or conventional colonoscopy. The procedure times for either NBI or conventional

colonoscopy were not significantly different. The NBI procedure (127 polyps, 62%) detected significantly more polyps versus conventional colonoscopy (78 polyps, 38%) ($p=0.014$). When the polyps were analysed by histology, 169 of 205 were found to be neoplastic. The NBI group had 103 neoplasms (60.9%) and the conventional colonoscopy group had 66 neoplasms (39.1%). The NBI technique detected more small adenomas compared to conventional colonoscopy ($p<0.05$). There were no significant adverse effects for either procedure reported at a two week follow up (Inoue et al. 2008) (Level III-2 diagnostic evidence).

A comparison of conventional colonoscopy and NBI was performed in 302 prospectively recruited patients. The patients were analysed in a sequential manner with polyps found by conventional colonoscopy re-analysed by NBI. The polyp's histology grades were predicted with both techniques and this was compared to the actual histology determined at a later date. The diagnostic accuracy of conventional colonoscopy and NBI versus histology were not different (77% versus 80%, $p=0.35$). However, there was an apparent learning curve associated with the NBI technique as its accuracy improved from 74 per cent to 87 per cent over the course of the trial. The sequential design only allowed the testing of the diagnostic accuracy of polyps known by conventional colonoscopy and did not allow for the potential for different rates of polyp detection with NBI that may have occurred if it was used in isolation (Rogart et al 2008) (Level III-2 diagnostic evidence).

Sikka et al compared NBI versus conventional colonoscopy with regard to correct prediction of histology status as determined later. The population consisted of 63 patients and these were analysed with both techniques sequentially. NBI showed a sensitivity of 95 per cent (correctly identified 93/98 neoplastic polyps) and a specificity of 90 per cent (correctly identified 56/62 non-neoplastic polyps). Conventional colonoscopy had a sensitivity of 59 per cent (correctly identified 58/98 neoplastic polyps) and a specificity of 76 per cent (correctly identified 47/62 non-neoplastic polyps). The overall diagnostic accuracy of NBI was 93 per cent and for conventional colonoscopy was 66 per cent ($p<0.0001$) (Sikka et al. 2008) (Level III-2 diagnostic evidence).

Most studies find that NBI performs at least equal to or better than conventional colonoscopy for the detection and prediction of the status of discovered polyps. Issues such as study design and learning curves were significant factors in some study outcomes.

COST IMPACT

No studies reported on the relative costs of NBI versus conventional colonoscopy. Olympus, manufacturer of the CF-Q180 AL colonoscope used in several studies in this prioritising summary, was contacted regarding the cost of a NBI capable colonoscope system but at the time of publication no reply was forthcoming.

- East, J. E., Saunders, B. P. et al (2007). 'Surface visualization at CT colonography simulated colonoscopy: effect of varying field of view and retrograde view', *Am J Gastroenterol*, 102 (11), 2529-2535.
- Inoue, T., Murano, M. et al (2008). 'Comparative study of conventional colonoscopy and pan-colonic narrow-band imaging system in the detection of neoplastic colonic polyps: a randomized, controlled trial', *J Gastroenterol*, 43 (1), 45-50.
- Kaltenbach, T., Friedland, S. & Soetikno, R. (2008). 'A Randomized Tandem Colonoscopy Trial of Narrow Band Imaging versus White Light Examination to compare Neoplasia Miss Rates', *Gut*.
- Kudo, S., Hirota, S. et al (1994). 'Colorectal tumours and pit pattern', *J Clin Pathol*, 47 (10), 880-885.
- Robertson, D. J., Greenberg, E. R. et al (2005). 'Colorectal cancer in patients under close colonoscopic surveillance', *Gastroenterology*, 129 (1), 34-41.
- Rogart, J. N., Jain, D. et al (2008). 'Narrow-band imaging without high magnification to differentiate polyps during real-time colonoscopy: improvement with experience', *Gastrointest Endosc*.
- Sikka, S., Ringold, D. A. et al (2008). 'Comparison of white light and narrow band high definition images in predicting colon polyp histology, using standard colonoscopes without optical magnification', *Endoscopy*.

SEARCH CRITERIA TO BE USED:

Colonic Polyps/*pathology
Colonoscopes
Colonoscopy/*methods
Diagnosis, Differential
Diagnostic Imaging/*instrumentation
Adenocarcinoma
Colorectal Neoplasms/*diagnosis/etiology
Colonic Neoplasms/diagnosis
Endoscopy, Gastrointestinal/*methods
Gastrointestinal Neoplasms/*diagnosis
Precancerous Conditions/diagnosis
Stomach Neoplasms/diagnosis